Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced last week in its Quarterly Report on Form 10-Q that it has encountered delays associated with the supply of …
Hemispherx BioPharma, Inc (NYSE:HEB), announced that as the Company works toward the re-launch of Alferon N, it has extended its agreement with Armada Health …
Hemispherx BioPharma, Inc (NYSE MKT:HEB) announced that the Board has appointed Thomas Equels as the new President for Hemispherx Biopharma Inc. According to Peter …
Hemispherx BioPharma, Inc (NYSEMKT:HEB), reported that it has executed an agreement with Emerge Health Pty Ltd. (“Emerge”) to seek approval of Alferon N Injection® …
Hemispherx BioPharma, Inc (NYSEMKT:HEB) reported today that it has executed an agreement with Impatients, N.V.
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announced that the United States District Court for the Eastern District of Pennsylvania has issued an order granting final …
Hemispherx BioPharma, Inc (NYSEMKT:HEB) announces that they have submitted an application for orphan drug designation to the European Medicines Agency (EMA) for Alferon N …
